Your browser doesn't support javascript.
Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping.
Lu, Yan; Wang, Yajun; Zhang, Zhen; Huang, Jingliang; Yao, Meicun; Huang, Guobin; Ge, Yuanyuan; Zhang, Peichun; Huang, Huaxin; Wang, Yong; Li, Huiliang; Wang, Wen.
  • Lu Y; Huamin Medicine Co Ltd., Zhuhai, China.
  • Wang Y; Wolfson Institute for Biomedical Research, University College London, London, UK.
  • Zhang Z; Joint Center for Life Sciences, School of Life Sciences, Tsinghua University, Beijing, China.
  • Huang J; School of Chemical Engineering and Technology, Sun Yat-sen University, Zhuhai, China.
  • Yao M; School of Pharmaceutical Sciences, Sun Yat-sen University, Shenzhen, China.
  • Huang G; Levi Regenerative Medicine Technologies, Zhuhai, China.
  • Ge Y; Levi Regenerative Medicine Technologies, Zhuhai, China.
  • Zhang P; Huamin Medicine Co Ltd., Zhuhai, China.
  • Huang H; Huamin Medicine Co Ltd., Zhuhai, China.
  • Wang Y; Guangzhou Hongxiang Biological Medicine Technology Co Ltd., Guangzhou, China.
  • Li H; Wolfson Institute for Biomedical Research, University College London, London, UK.
  • Wang W; Huamin Medicine Co Ltd., Zhuhai, China.
J Immunol Res ; 2020: 9465398, 2020.
Article in English | MEDLINE | ID: covidwho-879699
ABSTRACT
This new decade has started with a global pandemic of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), precipitating a worldwide health crisis and economic downturn. Scientists and clinicians have been racing against time to find therapies for COVID-19. Repurposing approved drugs, developing vaccines and employing passive immunization are three major therapeutic approaches to fighting COVID-19. Chicken immunoglobulin Y (IgY) has the potential to be used as neutralizing antibody against respiratory infections, and its advantages include high avidity, low risk of adverse immune responses, and easy local delivery by intranasal administration. In this study, we raised antibody against the spike (S) protein of SARS-CoV-2 in chickens and extracted IgY (called IgY-S) from egg yolk. IgY-S exhibited high immunoreactivity against SARS-CoV-2 S, and by epitope mapping, we found five linear epitopes of IgY-S in SARS-CoV-2 S, two of which are cross-reactive with SARS-CoV S. Notably, epitope SIIAYTMSL, one of the identified epitopes, partially overlaps the S1/S2 cleavage region in SARS-CoV-2 S and is located on the surface of S trimer in 3D structure, close to the S1/S2 cleavage site. Thus, antibody binding at this location could physically block the access of proteolytic enzymes to S1/S2 cleavage site and thereby impede S1/S2 proteolytic cleavage, which is crucial to subsequent virus-cell membrane fusion and viral cell entry. Therefore, the feasibility of using IgY-S or epitope SIIAYTMS-specific IgY as neutralizing antibody for preventing or treating SARS-CoV-2 infection is worth exploring.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Immunoglobulins / Coronavirus Infections / Epitope Mapping / Betacoronavirus Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: J Immunol Res Year: 2020 Document Type: Article Affiliation country: 2020

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Immunoglobulins / Coronavirus Infections / Epitope Mapping / Betacoronavirus Type of study: Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Animals / Humans Language: English Journal: J Immunol Res Year: 2020 Document Type: Article Affiliation country: 2020